Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative NALIRIFOX in Resectable Pancreatic Adenocarcinoma
NCT06816914Phase 2Recruiting
- Sponsor
- Taichung Veterans General Hospital
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nanoliposomal irinotecan in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Taichung Veterans General Hospital. Primary endpoint: 12-month Event-Free Survival Rate. Started Mar 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06816914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816914.